SWP
CRSP icon

Stratos Wealth Partners’s CRISPR Therapeutics CRSP Stock Holding History

Stratos Wealth Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,536
Closed -$245K – 1458
2024
Q2 		$245K Sell
4,536
-412
-8% -$23.8K ﹤0.01% 1171
2024
Q1 		$337K Sell
4,948
-1,452
-23% -$104K 0.01% 1050
2023
Q4 		$401K Buy
6,400
+820
+15% +$45.3K 0.01% 955
2023
Q3 		$253K Buy
5,580
+1,226
+28% +$63.3K 0.01% 1084
2023
Q2 		$244K Buy
+4,354
New +$247K 0.01% 1030
2022
Q4 		– Sell
-3,784
Closed -$247K – 1148
2022
Q3 		$247K Sell
3,784
-167
-4% -$12.1K 0.01% 937
2022
Q2 		$240K Sell
3,951
-41
-1% -$2.41K 0.01% 1021
2022
Q1 		$251K Buy
3,992
+211
+6% +$13.2K 0.01% 1057
2021
Q4 		$287K Buy
3,781
+200
+6% +$17.5K 0.01% 1016
2021
Q3 		$401K Buy
3,581
+95
+3% +$11.9K 0.01% 837
2021
Q2 		$564K Sell
3,486
-652
-16% -$79.3K 0.01% 727
2021
Q1 		$504K Sell
4,138
-67
-2% -$10.1K 0.01% 719
2020
Q4 		$644K Buy
4,205
+670
+19% +$79.2K 0.02% 592
2020
Q3 		$296K Sell
3,535
-720
-17% -$63.9K 0.01% 791
2020
Q2 		$313K Buy
+4,255
New +$249K 0.01% 759
2020
Q1 		– Sell
-3,660
Closed -$223K – 938
2019
Q4 		$223K Buy
+3,660
New +$200K 0.01% 871
2018
Q4 		– Sell
-1,570
Closed -$70K – 1130
2018
Q3 		$70K Buy
+1,570
New +$82.2K ﹤0.01% 1296
2018
Q2 		– Sell
-465
Closed -$21K – 1279
2018
Q1 		$21K Buy
+465
New +$19.2K ﹤0.01% 1992

Other funds holding CRSP

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Stratos Wealth Partners's CRSP Position: Q3 2024 in Review

Stratos Wealth Partners sold out of CRISPR Therapeutics (CRSP) in Q3 2024, closing a stake of 4,536 shares — an estimated $245K sold.

Stratos Wealth Partners first reported a position in CRSP in Q1 2018 and held it in 18 quarters. The position peaked at $644K in Q4 2020. 416 funds tracked by Wall St. Rank hold CRSP as of Q3 2024.

  • Stratos Wealth Partners reported no remaining CRISPR Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Stratos Wealth Partners sold 4,536 CRISPR Therapeutics shares in Q3 2024, an estimated $245K.
  • Stratos Wealth Partners first reported a position in CRISPR Therapeutics in Q1 2018 and held it in 18 quarters.
  • Stratos Wealth Partners's CRISPR Therapeutics position peaked at $644K in Q4 2020.
  • 416 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2024.

Based on Stratos Wealth Partners's 13F filing for Q3 2024, filed 17 Oct 2024.